New combo therapy offers hope for patients with stubborn lymphoma

NCT ID NCT07077512

First seen Jan 22, 2026 · Last updated Apr 22, 2026 · Updated 13 times

Summary

This study tests a combination of two treatments—relmacabtagene autoleucel (a type of cell therapy) and sintilimab (an immunotherapy drug)—in 30 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, mantle cell, and follicular lymphoma). The goal is to see if the combination can shrink tumors and control the disease. Participants must be willing to receive both treatments. This is not a cure, as ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fifth Affiliated Hospital of Guangzhou Medical University

    NOT_YET_RECRUITING

    Guangzhou, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Guangzhou overseas Chinese hospital

    NOT_YET_RECRUITING

    Guangzhou, 510632, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sun Yat-sen Universitiy Cancer Center

    RECRUITING

    Guangzhou, 51000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.